Summary
Following locoregional treatment, patients were randomized into three groups: The first group received no complementary treatment; the second group received adjuvant chemotherapy (vincristine, cyclophosphamide, and 5-fluorouracil once a month for 12 months); and the third group was treated by immunotherapy (150 mg BCG once a week for 1 year). Sixty-two of the 82 patients studied were menopausal. No significant difference was observed between the three groups. All patients were followed-up for at least 18 months. The disease-free interval difference between the chemotherapy group and the control and immunotherapy groups is not significant. But it should be noted that only 21.8% of the control group did not relapse compared to 57% in the chemotherapy group. BCG immunotherapy in such patients must be considered ineffective. However, our results suggest that patients first treated with BCG respond better to chemotherapy than patients not receiving any previous therapy.
For the EORTC Cancer Immunology and Immunotherapy Group (GI2C)
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Brusamolino E, Valagussa P et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–408
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915
Buzdar A, Blumenschein G, Hortobagyi G, Campos L, Hersh E (to be published) Adjuvant therapy with 5-fluorouracil, adriamycin and cyclophosphamide with or without BCG in stage II or III breast cancer. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Caraux J, Thierry C, Serrou B (1979) Human autologous rosettes. II. Prognostic significance of variations in autologous rosette-forming cells in the peripheral blood of cancer patients. J Natl Cancer Inst 63:593–597
Cuttner J, Glide well O, Holland J (to be published) A controlled trial of chemoimmunotherapy in acute myelocytic leukemia (AML). In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Dubois JB, Serrou B (1976) The treatment of the mouse Lewis tumor by the association of radiotherapy and BCG immunotherapy. Cancer Res 36:1731–1734
Dubois JB, Serrou B, Pourquier H (1975) Influence des traitements par rayonnements ionisants sur la réponse immunitaire du cancereux. Bull Cancer 62:1—20
Fisher B, Carbone P, Economou SG et al. (1975) L-Phenylalanine mustard in the management of primary breast cancer. N Engl J Med 292:117—120
FisherB, Glass A, Redmont C et al. (1977) L-PAM in the management of primary breast cancer. An update of earlier findings and comparison with those utilising L-PAM plus 5 FIU. Cancer 39:2883–2903
Gallagher JG, Louie AC, Sihora K, Levy R, Rosenberg SA, Merigan TC (to be published) The evaluation of human leukocyte interferon in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: A phase II study. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Jones S, Salmon S, Haskins C (to be published) Chemoimmunotherapy of non-Hodgkin’s lymphoma. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Klefstrom P, Holsti P, Grohn P, Heinonen E (to be published) Combination of levamisole immunotherapy with conventional treatments in breast cancer. In: Terry WD (ed) Immunotherapy of cancer: Present status of trials in man. Elsevier North-Holland, New York Oxford
Mathé G (1978) Systemic active immunotherapy is shifting from the middle ages to a renaissance period I. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease. Cancer Immunol Immunother 5:149–152
Mathé G, Serrou B (1979) Immunomodulateurs à visée cancérolytique et/ou cancérostatique. In: Giroux JP, Mathé G, Meyniel G (eds) Traité de pharmacologie clinique, vol 2. Expansion scientifique. Paris, pp 1797–1824
Rojas A, Seierstein J, Glait H, Olivari A (1977) Levamisole action in breast cancer stage III. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer – Present status of trials in man. Raven Press, New York, pp 635–645
Serrou B (to be published) Detrimental and favorable effects of radiotherapy on immune response of cancer patients. Toward a rational approach to radio-immunotherapeutic associations. In: Dubois JB, Serrou B, Rosenfeld C (eds) Immunopharmacological effects of irradiation. Raven Press, New York
Serrou B, Dubois JB (1977) Combination of radiotherapy and immunotherapy in the treatment of Lewis’s tumor. Eur J Cancer 13:489–494
Serrou B, Dubois JB (1978) Efficacy of BCG treatment after local radiotherapy in Lewis and MBL2 tumor-bearing mice. Cancer Immunol Immunother 4:209–213
Serrou B, Sancho-Garnier H, Cappelaere P et al. (1979) Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy. In: Bonadonna G, Mathé G, Salmon S (eds) Adjuvant therapies and markers of post-surgical minimal residual disease II. Springer, Berlin Heidelberg New York (Recent results in cancer research, vol 68, pp 105–108)
Serrou B, Sancho-Garnier H, Cappelaere et al. (1979) Improvement of disease-free interval by chemotherapy in T3-T4 breast cancer including majority of menopausal patients. 2nd International Conference on the Adjuvant Therapy of Cancer. Abstract p 27 – TUCSON
Serrou B, Goldstein AL, Thierry C, Caraux J (1979) Regulation of human suppressor cell function by thymosin. Biomedicine 31:89
Serrou B, Gauci L, Caraux J, Cupissol D, Thierry C, Esteve C (to be published) Immune imbalance in cancer patients. In: Mathé G, Muggia F (eds) Recent results in cancer research. Springer, Berlin Heidelberg New York
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Serrou, B. et al. (1982). Follow-Up Results from a Randomized Trial for T3 and T4 Breast Cancer Patients: Previous BCG Immunotherapy Improves Response to Chemotherapy in the Relapse Patient. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive